



FORM PTO-1449 (Modified)	ACTY. DOCKET NO.: C1039/7057	SERIAL NO.: 09/965,101
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Davis, et al.	
	FILING DATE: September 26, 2001	GROUP: Not Yet Assigned

U.S. PATENT DOCUMENTS


Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
<input checked="" type="checkbox"/>	*A1	3,906,092	09/16/75	Hilleman et al.	424	089	
<input checked="" type="checkbox"/>	*A2	4,844,904	07/04/89	Hamaguchi et al.	424	450	
<input checked="" type="checkbox"/>	*A3	4,863,740	09/05/89	Kissel et al.	424	450	
<input checked="" type="checkbox"/>	*A4	4,975,282	12/04/90	Cullis et al.	424	450	
<input checked="" type="checkbox"/>	*A5	5,000,959	03/19/91	Iga et al.	424	450	
<input checked="" type="checkbox"/>	*A6	5,248,670	09/28/93	Draper et al.	514	44	
<input checked="" type="checkbox"/>	*A7	5,580,859	12/03/96	Felgner et al.	514	44	
<input checked="" type="checkbox"/>	*A8	5,585,479	12/17/96	Hoke et al.	536	24.5	
<input checked="" type="checkbox"/>	*A9	5,589,466	12/31/96	Felgner et al.	514	44	
<input checked="" type="checkbox"/>	*A10	5,663,153	09/02/97	Hutcherson et al.	514	44	
<input checked="" type="checkbox"/>	*A11	5,679,647	10/21/97	Carson et al.	514	44	
<input checked="" type="checkbox"/>	*A12	5,723,335	03/03/98	Hutcherson et al.	435	375	
<input checked="" type="checkbox"/>	*A13	5,780,448	07/14/98	Davis et al.	514	44	
<input checked="" type="checkbox"/>	*A14	5,786,189	07/28/98	Locht et al.	435	172.3	
<input checked="" type="checkbox"/>	*A15	5,849,719	12/15/98	Carson et al.	514	44	10/04/96
<input checked="" type="checkbox"/>	A16	6,194,388 B1	02/27/01	Krieg, et al.			
<input checked="" type="checkbox"/>	A17	6,207,646 B1	03/27/01	Krieg, et al.			
<input checked="" type="checkbox"/>	A18	6,239,116 B1	05/29/01	Krieg, et al.			
<input checked="" type="checkbox"/>	A19	6,214,806 B1	04/10/01	Krieg, et al.			
<input checked="" type="checkbox"/>	A20	6,218,371 B1	04/17/01	Krieg, et al.			

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No	
<input checked="" type="checkbox"/>	*B1	WO 90/11092	10/04/90	PCT - Vical (Felgner)	A61K	48/00		
<input checked="" type="checkbox"/>	*B2	WO 91/12811	09/05/91	PCT - Isis Pharmaceuticals (Draper)	A61K	31/70		
<input checked="" type="checkbox"/>	*B3	0468520 A3	01/29/92	EPO - Mitsui Toatsu Chem. (Tokunaga)	A61K	31/70		
<input checked="" type="checkbox"/>	*B4	WO 92/03456	03/05/92	PCT - Isis Pharmaceuticals (Anderson)	C07H	15/12		
<input checked="" type="checkbox"/>	*B5	WO 92/18522	10/29/92	PCT - Salk Institute (Chu)	C07H	21/00		
<input checked="" type="checkbox"/>	*B6	WO 92/21353	12/10/92	PCT - Genta (Arnold)	A61K	31/70		
<input checked="" type="checkbox"/>	*B7	0302758 B1	03/16/94	EPO - NEMC (Androphy)	C12N	15/37		
<input checked="" type="checkbox"/>	*B8	WO 94/19945	09/15/94	PCT - Isis Pharmaceuticals (Draper)	A01N	43/04		
<input checked="" type="checkbox"/>	*B9	WO 95/05853	03/02/95	PCT - Regents of U. of Cal. (Carson)	A61K	48/00		
<input checked="" type="checkbox"/>	*B10	WO 95/26204	10/05/95	PCT - Isis Pharmaceuticals (Hutcherson)	A61K	48/00		
<input checked="" type="checkbox"/>	*B11	WO 96/02555	02/01/96	PCT - UIRF (Krieg)	C07H	21/00		
<input checked="" type="checkbox"/>	*B12	WO 96/13277	05/09/96	PCT - Regents of U. of Cal. (Carson)	A61K	48/00		
<input checked="" type="checkbox"/>	*B13	WO 96/14074	05/17/96	PCT - Regents of U. of Cal. (Carson)	A61K	31/70		
<input checked="" type="checkbox"/>	*B14	WO 96/35782	11/14/96	PCT - Applied Research Systems (C12N	15/00		
<input checked="" type="checkbox"/>	*B15	WO 97/28259	08/07/97	PCT - Regents of U. of Cal. (Carson)	C12N	15/00		

EXAMINER <i>DA</i>	DATE CONSIDERED 11/8/04
-----------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.



FORM PTO-1449 (Modified)	ATTY. DOCKET NO.: C1039/7057	SERIAL NO.: 09/965,101
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Devis, et al.	
	FILING DATE: September 26, 2001	GROUP: Not Yet Assigned

<i>DP</i>	*B16	WO 98/14210	04/09/98	PCT - Regents of U. of Cal. (Carson)	A61K	39/35		
	*B17	WO 98/52581	11/26/98	WIPO	A61K	35/00		
	*B18	WO 99/41368A2	08/19/99	WIPO	C12N	15/10		
	*B19	WO 99/41368A3	08/19/99	WIPO	C12N	15/10		
	*B20	EP 0773295	05/14/97					
	*B21	WO 98/18810	05/07/98	WIPO				
	*B22	WO 98/37919	09/03/98	WIPO				
	*B23	WO 98/40100	09/17/98	WIPO				
	*B24	WO 98/52581	11/26/98	WIPO				
	*B25	WO 99/51259	10/14/99	WIPO				
	*B26	WO 99/56755	11/11/99	WIPO				
	*B27	WO 99/58118	11/18/99	WIPO				
	*B28	WO 99/61056	12/02/99	WIPO				


OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

<i>DTM</i>	*C1	Adya N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. <i>Proc Natl Acad Sci USA</i> 91(12):5642-6, 7 Jun 1994.
<i>f</i>	*C2	Allison AC et al., The development of an adjuvant formulation that elicits cell-mediated and humoral immune responses to virus subunit and other antigens. <i>Immunopharmacology of Infections Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance</i> , pgs. 191-201, 1987.
	*C3	Angier N., Microbe DNA seen as alien by immune system, <i>New York Times</i> , 11 April 1995
	*C4	Azad RF et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, September, 1993.
	*C5	Azuma I, Biochemical and immunological studies on cellular components of tubercle bacilli. <i>Kekkaku</i> 69(9):45-55, 1992.
	*C6	Ballas ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol</i> 157(5):1840-5, 1996.
	*C7	Bayever, E et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. <i>Antisense Res Dev</i> 3:383-390, 1993.
	*C8	Bennett RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. <i>J Clin Invest</i> 76(6):2182-90, 1985.
	*C9	Berg DJ et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxin shock and the Shwartzman reaction but not endotoxin tolerance. <i>J Clin Invest</i> 96(5):2339-47, 1995.
	*C10	Blanchard DK et al., Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. <i>J Immunol</i> 136(3):963-70, 1986.
	*C11	Blaxter ML et al., Genes expressed in <i>Brugia malayi</i> infective third stage larvae. <i>Molecular and Biochemical Parasitology</i> 77:77-93, 1996.
	*C12	Boggs RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev</i> 7(5):461-71, Oct 1997.
	*C13	Branda RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J Lab Clin Med</i> 128(3):329-38, Sep 1996.
	*C14	Branda RF et al., immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. <i>Biochemical Pharmacology</i> 45(10):2037-2043, 1993.

Doh

1108/04



FORM PTO-1449 (Modified)	INVENTOR: [blank]	DOCKET NO.: C1039/7057	SERIAL NO.: 09/965,101
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Davis, et al.		
	FILING DATE: September 26, 2001		GROUP: Not Yet Assigned

OTHER ART		(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)
DM	*C15	Briskin M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation. <i>Mol Cell Biol</i> 10(1):422-5, Jan 1990.
	*C16	Burgess TL et al., The antiproliferative activity of c-myc and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. <i>Proc Natl Acad Sci USA</i> 92(9):4051-5, 1995.
	*C17	Chace J et al., Regulation of differentiation in CD5+ and conventional B cells. <i>Clinical Immunology and Immunopathology</i> 68(3):327-332, 1993.
	*C18	Chang YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. <i>J Virol</i> 64(1):264-77, Jan 1990.
	*C19	Chu RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med</i> 186(10):1623-31, 17 Nov 1997.
	*C20	Condon C et al., DNA-based immunization by in vivo transfection of dendritic cells. <i>Nat Med</i> 2(10):1122-8, 1996.
	*C21	Corr M et al., Gene vaccination with naked plasmid DNA: mechanism of CTL priming. <i>J Exp Med</i> 184(4):1555-60, 1996.
	*C22	Cowdery JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. <i>J Immunol</i> 156(12):4570-5, 15 Jun 1996.
	*C23	Crosby SD et al., The early response gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG (GSG) element-binding protein family. <i>Mol Cell Biol</i> 2:3835-3841, 1991.
	*C24	Crystal RG, Transfer of genes to humans: early lessons and obstacles to success. <i>Science</i> 270:404-410, 1995.
	*C25	D'Andrea A et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. <i>J Exp Med</i> 178(3):1041-8, 1993.
	*C26	Davis HL et al., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. <i>J Immunol</i> 160(2):870-6, 1998.
	*C27	Davis HL et al., Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. <i>Hum Gene Ther</i> 4(2):151-9, 1993.
	*C28	Davis HL et al., DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. <i>Proc Natl Acad Sci USA</i> 93(14):7213-8, 1996.
	*C29	Davis HL et al., DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. <i>Hum Mol Genet</i> 2(11):1847-51, 1993.
	*C30	Davis HL, Plasmid DNA expression systems for the purpose of immunization. <i>Curr Opin Biotechnol</i> 8(5):635-46, 1997.
	*C31	Doe B et al., Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. <i>Proc Natl Acad Sci USA</i> 93:8578-8583, 1996.
	*C32	Englisch U et al., Chemically modified oligonucleotides as probes and inhibitors, <i>Angew Chem Int Ed Engl</i> 30:613-629, 1991.
	*C33	Erb KJ et al., Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. <i>J Exp Med</i> 187(4):561-9, 16 Feb 1998.
	*C34	Etchart N et al., Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. <i>J Gen Virol</i> 78(7):1577-80, 1997.
	*C35	Etlinger HM, Carrier sequence selection - one key to successful vaccines. <i>Immunology Today</i> 13(2):52-55, 1992.
	*C36	Fox RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug. <i>Chemical Abstracts</i> , 120:15, Abstract No. 182630 (29 April 1994).
	*C37	Fynan EF et al., DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. <i>Proc Natl Acad Sci USA</i> 90(24):11478-82, 1993.
	*C38	Gramzinski RA et al., Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. <i>Mol Med</i> 4(2):109-18, 1998.

1/08/04


FORM PTO-1449 (Modified)	ATTY. DOCKET NO.: C1039/7057	SERIAL NO.: 09/965,101
	APPLICANT: Davis, et al.	
	FILING DATE: September 26, 2001	GROUP: Not Yet Assigned

OTHER ART
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

<i>DN</i>	*C39	Gura, T., Antisense Has Growing Pains. <i>Science</i> 270:575-576, 1995.
	*C40	Hadden JW et al., Immunopharmacology: immunomodulation and immunotherapy. <i>JAMA</i> 268(20):2964-2969, 1992.
	*C41	Hadden JW, Immunostimulants. <i>TIPS</i> 14:169-174, 1993.
	*C42	Halpern MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol</i> 167(1):72-8, 1996.
	*C43	Harms JS and Splitter GA, Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. <i>Hum Gene Ther</i> 6(10):1291-7, 1995.
	*C44	Hatzfeld J et al., Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides. <i>J Exp Med</i> 174:925-929, 1991.
	*C45	Highfield-PE, Sepsis: the more, the murkier. <i>Bioethology</i> 12:828, 12 August 1994.
	*C46	Hoeffler JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. <i>Mol Endocrinol</i> 5(2):256-66, Feb 1991.
	*C47	Iguchi-Ariga SM and Shaffner W, CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> 3(5):612-9, May 1989.
	*C48	International Search Report, PCT/US98/10408, WO 98/52581, 2 September 1998.
	*C49	Ishikawa R et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol</i> 150(9):3713-27, 1 May 1993.
	*C50	Iversen P et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. <i>Antisense Res Dev</i> 4:43-52, 1994.
	*C51	Jakway JP et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products. <i>J Immunol</i> 137(7):2225-31, 1 Oct 1986.
	*C52	Jaroszewski JW and Cohen JS, Cellular uptake of antisense oligonucleotides. <i>Adv Drug Delivery Rev</i> 6(3):235-50, 1991.
	*C53	Kimura Y et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. <i>J Biochem</i> 116(5):991-994, 1994.
	*C54	Kline JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. <i>J Invest Med</i> 44(7):380A, 1996.
	*C55	Kline JN et al., CpG oligonucleotides can reverse as well as prevent Th2-mediated inflammation in a murine model of asthma. <i>J Invest Med</i> 45(7):298A, 1997.
	*C56	Kline JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. <i>J Invest Med</i> 45(3):282A, 1997.
	*C57	Klinman DM et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol</i> 158:3635, 1997.
	*C58	Klinman DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci USA</i> 93(7):2879-83, 1996.
	*C59	Krieg AM et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. <i>J Immunol</i> 143:2448-2451, 1989.
	*C60	Krieg AM et al., CpG DNA: A pathogenic factor in systemic lupus erythematosus? <i>J Clin Immunol</i> 15(6):284-292, 1995.
	*C61	Krieg AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> 374:546-9, 1995.
	*C62	Krieg AM et al., Leukocyte stimulation by oligodeoxynucleotides. <i>Applied Antisense Oligonucleotide Technology</i> 431-448, 1998.

Davis

11/08/04



FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: C1039/7057		SERIAL NO.: 09/965,101
	APPLICANT: Davis, et al.		
	FILING DATE: September 26, 2001		GROUP: Not Yet Assigned

OTHER ART (Including Author, Title, Date, Pertinent Pages, Publication, Etc.)		
*C63	Krieg AM et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. <i>Proc Natl Acad Sci USA</i> 90:1048-1052, 1993.	
*C64	Krieg AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev</i> 6(2):133-9, Summer 1996.	
*C65	Krieg AM et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? <i>Antisense Res Dev</i> 5:241, 1995.	
*C66	Krieg AM et al., The role of CpG dinucleotides in DNA vaccines. <i>Trends in Microbiology</i> 6:23-27, Jan 1998.	
*C67	Krieg AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev</i> 1(2):161-71, Summer 1991.	
*C68	Krieg AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>J Lab Clin Med</i> 128(2):128-33, 1996.	
*C69	Kuramoto E et al., Oligonucleotide sequences required for natural killer cell activation. <i>Jpn J Cancer Res</i> 83:1128-1131, November 1992.	
*C70	Leclerc C et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. <i>Cell Immunol</i> 179(2):97-106, 1997.	
*C71	Leonard GA et al., Conformation of guanine 8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(O8A)GCG). <i>Biochemistry</i> 31(36):8415-8420, 1992.	
*C72	Lipford GB et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol</i> 27(9):2340-4, 1997.	
*C73	Liu MA et al., Immunization of non-human primates with DNA vaccines. <i>Vaccine</i> 15(8):909-12, 1997.	
*C74	Macfarlane DE and Manzel L, Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. <i>J Immunol</i> 160(3):1122-31, 1 Feb 1998.	
*C75	Mannino RJ et al., Lipid matrix-based vaccines for mucosal and systemic immunization. <i>Vaccine Design: The Subunit and Adjuvant Approach</i> , Chapter 15, pp. 363-387, 1995.	
*C76	Mastrangelo MJ et al., Gene therapy for human cancer. <i>Seminars in Oncology</i> 23(1):4-21, 1996.	
*C77	Matson S and Krieg AM, Nonspecific suppression of [³ H]thymidine incorporation by "control" oligonucleotides. <i>Antisense Res Dev</i> 2(4):325-30, Winter 1992.	
*C78	McIntyre KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. <i>Antisense Res Dev</i> 3(4):309-22, Winter 1993.	
*C79	Messina JP et al., Stimulation of <i>in vitro</i> murine lymphocyte proliferation by bacterial DNA. <i>J Immunol</i> 147(6):1759-1764, 15 September 1991.	
*C80	Messina JP et al., The influence of DNA structure on the <i>in vitro</i> stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. <i>Cell Immunol</i> 147:148-157, 1993.	
*C81	Mojcik CF et al., Administration of a phosphorothioate oligonucleotide antisense murine endogenous retroviral MCF <i>env</i> causes immune effects <i>in vivo</i> in a sequence-specific manner. <i>Clinical Immunology and Immunopathology</i> 67(2):130-136, 1993.	
*C82	Mottram JC et al., A novel CDC2-related protein kinase from <i>Leishmania mexicana</i> , LmmCRK1, is post-translationally regulated during the life cycle. <i>J Biol Chem</i> 268(28):21044-21052, October 1993.	
*C83	<i>New England BIOLABS 1988-1989 Catalog</i>	
*C84	Nyce JW and Metzger WJ, DNA antisense therapy for asthma in an animal model. <i>Nature</i> 385:721-725, 20 Feb 1997.	
*C85	Pisetsky DS and Reich C, Stimulation of <i>in vitro</i> proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. <i>Mol Biol Rep</i> 18(3):217-221, 1993.	
*C86	Pisetsky DS and Reich CF, Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Science</i> 54:101-107, 1994.	
*C87	Pisetsky DS, Immunologic consequences of nucleic acid therapy. <i>Antisense Res Dev</i> 5:219-225, 1995.	

Davis

11/08/00




FORM PTO-1449 (Modified)	ATTY. DOCKET NO.: C1039/7057	SERIAL NO.: 09/965,101
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Davis, et al.	
	FILING DATE: September 26, 2001	GROUP: Not Yet Assigned

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

*C88	Pisetsky DS, The immunologic properties of DNA. <i>J Immunol</i> 156(2):421-423, 1996.
*C89	Prince AM et al., Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. <i>Vaccine</i> 15(8):916-9, 1997.
*C90	Raz E et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. <i>Proc Natl Acad Sci USA</i> 91(20):9519-23, 1994.
*C91	Raz E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci USA</i> 93(10):5141-5, 14 May 1996.
*C92	Roman M et al., Immunostimulatory DNA sequences function as T helper-I-promoting adjuvants. <i>Nat Med</i> 3(8):849-54, Aug 1997.
*C93	Sato Y et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. <i>Science</i> 273(5273):352, 19 July 1996.
*C94	Schnell N et al., Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PARI) conferring resistance to iron chelators. <i>Eur J Biochem</i> 200:487-493, 1991.
*C95	Schwartz DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest</i> 100(1):68-73, 1 Jul 1997.
*C96	Schwartz DA et al., Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. <i>Am J Physiol</i> 267(5 Pt 1):L609-17, 1994.
*C97	Schwartz DA et al., The role of endotoxin in grain dust-induced lung disease. <i>Am J Respir Crit Care Med</i> 152(2):603-8, 1995.
*C98	Shirakawa T et al., The inverse association between tuberculin responses and atopic disorder. <i>Science</i> 275(5296):77-9, 3 Jan 1997.
*C99	Sparwasser T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor- α -mediated shock. <i>Eur J Immunol</i> 27(7):1671-9, Jul 1997.
*C100	Stein CA et al., Oligonucleotides as inhibitors of gene expression: a review. <i>Cancer Res</i> 48:2659-2668, 1988.
*C101	Stull RA et al., Antigene, ribozyme, and aptamer nucleic acid drugs: progress and prospects. <i>Pharmaceutical Res</i> 12(4):465-483, 1995.
*C102	Subramanian PS et al., Theoretical considerations on the "spine of hydration" in the minor groove of d(CGCGAATTCGCG)-d(GCGCTTAAGCGC): Monte Carlo computer simulation. <i>Proc Natl Acad Sci USA</i> 85:1836-1840, 1988.
*C103	Tanaka T et al., An antisense oligonucleotide complementary to a sequence in Iy2b increases γ 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. <i>J Exp Med</i> 175:597-607, 1992.
*C104	Tang D-C et al., Genetic immunization is a simple method for eliciting an immune response. <i>Nature</i> 356(6365):152-4, 1992.
*C105	Thorne PS, Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. <i>Am J Ind Med</i> 25(1):109-12, 1994.
*C106	Tokunaga T et al., A synthetic single-stranded DNA, poly (dG,dC), induces interferon α/β and $-\gamma$, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res</i> 79:682-686, June 1988.
*C107	Tokunaga T et al., Synthetic oligonucleotides with particular base sequences form the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol</i> 36(1):55-66, 1992.
*C108	Tomasi M et al., Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization. <i>Eur J Immunol</i> 27:2720-2725, 1997.
*C109	Uhlmann E et al., Antisense oligonucleotides: a new therapeutic principle. <i>Chem Rev</i> 90:543-584, 1990.
*C110	Wagner RW, Gene inhibition using antisense oligodeoxynucleotides. <i>Nature</i> 372:333-335, 1994.


1/08/04



FORM PTO-1449 (Modified)	PROPERTY DOCKET NO.: C1039/7057	SERIAL NO.: 09/965,101
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Davis, et al.	
	FILING DATE: September 26, 2001	GROUP: Not Yet Assigned

OTHER ART (Including Author, Title, Date, Pertinent Pages, Publication, Etc.)		
	*C111	Wallace RB et al., Oligonucleotide probes for the screening of recombinant DNA libraries. <i>Methods in Enzymology</i> 152:432-442, 1987.
	*C112	Weiner GJ et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proc Natl Acad Sci USA</i> 94(20):10833-7, 1997.
	*C113	Weiss R, Upping the antisense ante: Scientists bet on profits from reverse genetics. <i>Science</i> 139:108-109, 1991.
	*C114	Whalen RG, DNA vaccines for emerging infection diseases: what if? <i>Emerging Infectious Disease</i> 2(3):168-175, 1996.
	*C115	Wu GY et al., Receptor-mediated gene delivery and expression in vivo. <i>J Biol Chem</i> 263:14621-14624, 1988.
	*C116	Wu-Pong S, Oligonucleotides: opportunities for drug therapy and research. <i>Pharmaceutical Technology</i> 18:102-114, 1994.
	*C117	Xiang ZQ et al., The effect of interferon-gamma on genetic immunization. <i>Vaccine</i> 15(8):896-8, 1997.
	*C118	Yamamoto S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. <i>Microbiol Immunol</i> 36(9):983-97, 1992.
	*C119	Yamamoto S et al., <i>In vitro</i> augmentation of natural killer cell activity and production of interferon-alpha/beta and gamma with deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res</i> 79:866-73, Jul 1988.
	*C120	Yamamoto S et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. <i>J Immunol</i> 148(12):4072-4076, 15 June 1992.
	*C121	Yamamoto S, Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG. <i>Kekkaku</i> 69(9):29-32, 1994.
	*C122	Yamamoto T et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. <i>Antisense Res Dev</i> 4:119-123, 1994.
	*C123	Yamamoto T et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence AACGTT to murine splenocytes enhances interferon production and natural killer activity. <i>Microbiol Immunol</i> 38(10):831-836, 1994.
	*C124	Yamamoto T et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes <i>in vitro</i> . <i>Jpn J Cancer Res</i> 85:775-779, 1994.
	*C125	Yaswen P et al., Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. <i>Antisense Res Dev</i> 3(1):67-77, 1993.
	*C126	Yi, A-K et al., IFN- γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides. <i>J Immunol</i> 156(2):558-564, 1996.
	*C127	Yi, A-K et al., Rapid immune activation by CpG motifs in bacterial DNA. <i>J Immunol</i> 157(12):5394-5402, 1996.
	*C128	Zhao Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> 3(1):53-66, Spring 1993.
	*C129	Zhao Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> 84(11):3660-6, 1 Dec 1994.
	*C130	Cox CJM, et al. Bovine herpes virus 1: immune responses in mice and cattle injected with plasmid DNA. <i>J. Virol</i> 1993 Sep; 67(9):5664-5667
	*C131	Lipford GB et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. <i>Eur J Immunol</i> 1997 Dec; 27(12):3420-3426
	*C132	Morahan PS et al. Comparative analysis of modulators of nonspecific resistance against microbial infections. <i>Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Nonspecific Resistance</i> . 1987. Alan R. Liss, pp. 313-324.
	*C133	Parker SE et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. <i>Cancer Gene Therapy</i> 1996 May-Jun;3(3):175-1785

1/08/04



FORM PTO-1449 (Modified)	AGENCY DOCKET NO.: C1039/7057	SERIAL NO.: 09/965,101
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Davis, et al.	
	FILING DATE: September 26, 2001	GROUP: Not Yet Assigned

OTHER ART (Including Author, Title, Date, Pertinent Pages, Publication, Etc.)		
<input checked="" type="checkbox"/>	*C134	Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993 March 19;259:1745-1749
<input checked="" type="checkbox"/>	*C135	Vogels MTE et al. Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrob Agent Chemother 1992 Jan;36(1):1-5
<input checked="" type="checkbox"/>	*C136	Wang B et al. Gene inoculation generates immune responses against human immunodeficiency virus type I. Proc Natl Acad Sci USA 1993 May;90:4156-4160
<input checked="" type="checkbox"/>	*C137	Wloch MK et al. The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. Human Gene Therapy 1998 Jul 1;9:1439-1447
<input checked="" type="checkbox"/>	*C138	Karlin S et al. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses? J Virol. 1994 May;68(5):2889-2897
<input checked="" type="checkbox"/>	*C139	Krieg AM et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998 Oct 13;95(21):12631-12636
<input checked="" type="checkbox"/>	*C140	Schreiber E et al. Long-range activation of transcription by SV40 enhancer is affected by "inhibitory" or "permissive" DNA sequences between enhancer and promoter. Somat Cell Mol Genet. 1989 Nov;15(6):591-603
<input checked="" type="checkbox"/>	*C141	Verma, et al. Gene therapy promises, problems and prospects, Nature 1997 Sept;389: 239-242
<input checked="" type="checkbox"/>	*C142	Anderson, et al. Human Gene Therapy, Nature 1998 April; 392: 25-30
<input checked="" type="checkbox"/>	*C143	McCluskie, et al. Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates, Molecular Medicine, 1999;5: 287-300
<input checked="" type="checkbox"/>	*C144	Cryz, et al. Vaccine Delivery Systems, Reports of the Expert Panels, Vaccine 1996;14(7): 665-688

* A copy was cited in the parent application having serial number 09/082,649, filed May 20, 1998.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.